Global Molecular Clostridium Difficile Diagnostic Equipment Market Research Report 2022

Clostridium difficile infection (CDI or C-dif) is a symptomatic infection due to the spore-forming bacterium, Clostridium difficile.[2] Symptoms include watery diarrhea, fever, nausea, and abdominal pain. It makes up about 20% of cases of antibiotic-associated diarrhea. Complications may include pseudomembranous colitis, toxic megacolon, perforation of the colon, and sepsis.
Due to the COVID-19 pandemic, the global Molecular Clostridium Difficile Diagnostic Equipment market size is estimated to be worth US$ million in 2021 and is forecast to a readjusted size of US$ million by 2028 with a CAGR of % during the forecast period 2022-2028. Fully considering the economic change by this health crisis, the Europe Molecular Clostridium Difficile Diagnostic Equipment market is estimated at US$ million in 2022, while the United States and China are forecast to reach US$ million and US$ million by 2028, respectively. The proportion of the United States is % in 2022, while Chinese percentage is %, and it is predicted that China market share will reach % in 2028, trailing a CAGR of % through the analysis period. As for the Europe Molecular Clostridium Difficile Diagnostic Equipment landscape, Germany is projected to reach US$ million by 2028. and in Asia, the notable markets are Japan and South Korea, CAGR is % and % respectively for the next 6-year period.
Portable accounting for % of the Molecular Clostridium Difficile Diagnostic Equipment global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals & Clinics segment is altered to an % CAGR throughout this forecast period and will hold a share about % in 2028.
The global major manufacturers of Molecular Clostridium Difficile Diagnostic Equipment include Roche, Thermo Fisher Scientific, Merck, Pfizer, Actelion Pharmaceuticals, Abbott Laboratories, Trinity Biotech, Summit Therapeutics and Baxter International, etc. In terms of revenue, the global 3 largest players have a % market share of Molecular Clostridium Difficile Diagnostic Equipment in 2021.
This report focuses on Molecular Clostridium Difficile Diagnostic Equipment volume and value at the global level, regional level, and company level. From a global perspective, this report represents overall Molecular Clostridium Difficile Diagnostic Equipment market size by analysing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan, etc.
Global Molecular Clostridium Difficile Diagnostic Equipment Market: Segment Analysis
The research report includes specific segments by region (country), by company, by Type and by Application. This study provides information about the sales and revenue during the historic and forecasted period of 2017 to 2028. Understanding the segments helps in identifying the importance of different factors that aid the market growth.
Segment by Type
Portable
Desktop
Segment by Application
Hospitals & Clinics
Diagnostic Laboratories
Others
By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
By Company
Roche
Thermo Fisher Scientific
Merck
Pfizer
Actelion Pharmaceuticals
Abbott Laboratories
Trinity Biotech
Summit Therapeutics
Baxter International
Sanofi
Novartis
AstraZeneca